Yangzijiang grabs over $1 billion in antithrombotic drug sales growth of 54,767%

On January 14, Nanjing Hailing Pharmaceutical, a Yangtze River Pharmaceutical Group, submitted an application for the listing of 4 types of edoxaban tosylate tablets.
At present, there is no domestic generic drug of this product on the market.
Hainan Simcere Pharmaceutical, Nanjing Zhengda Pharmaceutical Co.
, Ltd.
Tianqing Pharmaceutical has already applied for production, all of which are under review and approval, and the battle for the first imitation is intensifying
.
Edoxaban is a selective factor Xa inhibitor developed by Daiichi Sankyo.
It was first approved for venous thromboembolism in Japan in 2011, and has since been approved for multiple new indications.
Global sales in 2020 amounted to 154.
1 billion yen (about 1.
3 billion US dollars)
.
The original research product was approved to enter the domestic market at the end of 2018.
According to Minet.
com data, in the first half of 2021, in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) terminals, the original research products are sold.
The sales growth rate is as high as 54766.
67%, and the market potential should not be underestimated
.
At present, the xaban products listed in the domestic market include apixaban tablets, rivaroxaban tablets and edoxaban tosylate tablets, of which apixaban tablets and rivaroxaban tablets have been domestically imitated and obtained.
In recent years, edoxaban tosylate tablets have also attracted a number of domestic star pharmaceutical companies to compete for the first imitation, and Nanjing Hailing Pharmaceutical of Yangzijiang Pharmaceutical Group is the third company to apply for production.
In the end, who will be the first imitation flower? We will wait and see
.
Table 1: The TOP5 varieties of antithrombotic drugs in the retail market Source: Minet.
com China's urban physical pharmacy terminal competition Figure 1: Sales of rivaroxaban in the past three years (unit: 100 million yuan) Source: Minet.
com China's urban physical pharmacy terminal Competitive Landscape It is reported that antithrombotic drugs such as saban play an important role in the treatment, prevention and treatment of thromboembolic diseases, which alleviate the shortcomings of traditional drugs such as heparin and warfarin
.
According to the data of Minet.
com, among the TOP5 anti-thrombotic drugs in Chinese urban physical pharmacies in 2021E, only rivaroxaban has maintained a positive growth trend.
In addition, apixaban has also squeezed into the top ten, and xaban drugs are growing into a new type of drug.
Representative of Oral Antithrombotic Drugs
.
Yangzijiang won the production approval for rivaroxaban tablets in 2020, and approved apixaban tablets in 2021, all of which were approved according to the new classification as a review, pending the approval of edoxaban tosylate tablets After the listing, Yangzijiang, which holds three potential products, will explode new vitality in the antithrombotic drug market
.
Source: CDE official website, Minet database